secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001628280-23-017420
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine appoints Jeff Marrazzo to board of directors
-----------------------------------------------------------

- Jeff Marrazzo appointed as Class II director effective May 10, 2023, until 2024 annual meeting.
- Granted stock options for 92,000 shares vesting in three equal annual installments.
- Annual cash compensation of $40,000 for board service and $6,000 for Compensation Committee.
- Also appointed to the Compensation Committee.
- No arrangements or transactions requiring disclosure under Item 404(a).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023017420/0001628280-23-017420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828023017420/prme-20230510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-017420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer